Pharma BD Deal Intelligence
PTC Therapeutics agreed to acquire Censa Pharmaceuticals to add Phase 3-ready CNSA-001 (sepiapterin) for PKU and BH4 pathway metabolic diseases. Deal: $10M cash + ~850,000 PTC shares (~$41M) upfront, plus up to $217.5M in development/regulatory milestones across the two most advanced programs. Phase 2 trial in PKU met primary and secondary endpoints in December 2019. OUTCOME (post-close, sourced 2026-06): The acquired asset CNSA-001/sepiapterin (developed as PTC923) won triple regulatory approval as Sephience™ — EU marketing authorization (European Commission, announced June 23, 2025; CHMP positive opinion April 25, 2025), FDA approval (July 28, 2025; NDA 219666, for sepiapterin-responsive PKU in patients 1 month and older), and Japan MHLW approval (December 22, 2025) — all based on the Phase 3 APHENITY trial. The three approvals within ~6 months confirm the 2020 deal thesis and realize the regulatory-milestone arm of the earn-out.
Assessment window: 5yr post-close.